Profile data is unavailable for this security.
About the company
Adlai Nortye Ltd is a global clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The Company’s pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as three preclinical candidates. AN2025 is a pan-phosphoinositide 3-kinase (PI3K) inhibitor that is designed to act against solid tumors. AN2025 is undergoing Phase III, open-label clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) after anti-programmed death-1 (PD-1) or its ligand (PD-L1) treatment. AN0025 is a small molecule prostaglandin E receptor 4 (EP4) antagonist. AN4005 is an internally discovered oral small molecule PD-L1 inhibitor in development to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include: AN8025, AN1025, and AN9025.
- Revenue in USD (TTM)5.00m
- Net income in USD-104.87m
- Incorporated2018
- Employees127.00
- LocationAdlai Nortye Ltdc/o Ugland HousePO Box 309GRAND CAYMAN KY1-1104Cayman IslandsCYM
- Phone+1 8 482307430
- Websitehttp://www.adlainortye.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Applied Therapeutics Inc | -477.00k | -193.56m | 485.64m | 26.00 | -- | 7.22 | -- | -- | -1.91 | -1.91 | -0.005 | 0.589 | -0.0053 | -- | -- | -19,080.00 | -213.60 | -140.37 | -604.11 | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
| Esperion Therapeutics Inc | 229.74m | -86.51m | 490.70m | 240.00 | -- | -- | -- | 2.14 | -1.00 | -1.00 | 1.76 | -1.57 | 0.7353 | 0.7415 | 5.05 | 957,250.00 | -27.69 | -69.45 | -47.42 | -101.81 | 81.85 | -- | -37.65 | -147.44 | 1.78 | -0.6581 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -33.76m | 490.73m | 19.00 | -- | 4.98 | -- | -- | -6.97 | -6.97 | 0.00 | 9.23 | 0.00 | -- | -- | 0.00 | -38.06 | -86.84 | -49.24 | -130.46 | -- | -- | -- | -769.76 | -- | -15.43 | 0.1179 | -- | -- | -- | -5.33 | -- | -- | -- |
| Entrada Therapeutics Inc | 162.87m | 23.49m | 504.70m | 160.00 | 23.83 | 1.87 | 18.84 | 3.10 | 0.6273 | 0.6273 | 4.79 | 8.02 | 0.3302 | -- | 3.89 | 1,024,359.00 | 4.76 | -- | 7.06 | -- | -- | -- | 14.42 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -108.30m | 509.21m | 118.00 | -- | 4.71 | -- | -- | -3.14 | -3.14 | 0.00 | 2.56 | 0.00 | -- | -- | 0.00 | -68.23 | -33.56 | -75.55 | -36.55 | -- | -- | -- | -941.88 | -- | -- | 0.00 | -- | -- | -- | -12.83 | -- | -3.47 | -- |
| Travere Therapeutics Inc | 155.72m | -415.73m | 509.30m | 380.00 | -- | 6.87 | -- | 3.27 | -5.32 | -2.00 | 2.04 | 0.9732 | 0.2116 | 1.57 | 7.04 | 409,800.00 | -56.49 | -36.95 | -71.19 | -44.77 | 94.34 | 95.92 | -266.96 | -165.79 | 2.75 | -- | 0.836 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| Ocugen Inc | 7.05m | -58.50m | 509.51m | 65.00 | -- | 16.84 | -- | 72.27 | -0.2348 | -0.2348 | 0.028 | 0.1176 | 0.0952 | -- | -- | 108,461.50 | -79.01 | -83.56 | -100.56 | -97.79 | -- | -- | -829.84 | -2,921.94 | -- | -- | 0.0855 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
| Adlai Nortye Ltd (ADR) | 5.00m | -104.87m | 512.91m | 127.00 | -- | 6.46 | -- | 102.58 | -7.26 | -7.26 | 0.1931 | 2.15 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -2,097.42 | -- | -- | -1.69 | 0.2843 | -- | -- | -- | -78.38 | -- | -- | -- |
| Astria Therapeutics Inc | 0.00 | -81.63m | 517.83m | 59.00 | -- | 1.90 | -- | -- | -2.32 | -2.32 | 0.00 | 6.70 | 0.00 | -- | -- | 0.00 | -27.34 | -64.48 | -28.18 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
| Y-mAbs Therapeutics Inc | 84.50m | -21.67m | 520.01m | 100.00 | -- | 5.24 | -- | 6.15 | -0.496 | -0.496 | 1.93 | 2.26 | 0.6481 | 1.31 | 4.30 | 844,990.00 | -16.62 | -44.23 | -19.95 | -50.45 | 86.53 | -- | -25.64 | -181.13 | 5.67 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
| Alector Inc | 96.41m | -120.61m | 529.15m | 244.00 | -- | 2.96 | -- | 5.49 | -1.39 | -1.39 | 1.12 | 1.86 | 0.1393 | -- | -- | 395,106.60 | -17.43 | -20.00 | -21.55 | -23.81 | -- | -- | -125.11 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
| OmniAB Inc | 21.05m | -63.48m | 535.15m | 106.00 | -- | 1.77 | -- | 25.43 | -0.634 | -0.634 | 0.2103 | 2.57 | 0.055 | -- | 7.18 | 198,547.20 | -16.58 | -- | -17.48 | -- | -- | -- | -301.63 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| Verve Therapeutics Inc | 16.05m | -196.83m | 535.70m | 255.00 | -- | 0.9172 | -- | 33.38 | -2.87 | -2.87 | 0.2309 | 6.96 | 0.0235 | -- | 4.48 | 62,937.25 | -28.80 | -- | -30.24 | -- | -- | -- | -1,226.43 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
| Absci Corp | 5.35m | -109.19m | 536.02m | 155.00 | -- | 2.23 | -- | 100.25 | -1.17 | -1.17 | 0.0569 | 2.12 | 0.0187 | -- | 7.82 | 34,496.77 | -38.26 | -- | -42.14 | -- | -- | -- | -2,042.01 | -- | -- | -107.74 | 0.0298 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
| Celcuity Inc | 0.00 | -63.78m | 537.80m | 55.00 | -- | 3.22 | -- | -- | -2.70 | -2.70 | 0.00 | 5.48 | 0.00 | -- | -- | 0.00 | -34.76 | -37.32 | -36.88 | -39.16 | -- | -- | -- | -- | -- | -- | 0.2095 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Cantor Fitzgerald & Co.as of 31 Dec 2023 | 40.31k | 0.13% |
| Millennium Management LLCas of 31 Dec 2023 | 22.59k | 0.07% |
| Qube Research & Technologies Ltd.as of 31 Dec 2023 | 84.00 | 0.00% |
| UBS Securities LLCas of 31 Dec 2023 | 0.00 | 0.00% |
